Olema Pharmaceuticals (OLMA) Stock Analysis

What Olema Pharmaceuticals does

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

Key metrics

ETFs linked to OLMA

Broad-market and Healthcare sector ETFs an investor holding Olema Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how OLMA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Olema Pharmaceuticals?

Olema Pharmaceuticals trades under the ticker OLMA on NASDAQ.

Which exchange is OLMA listed on?

OLMA is listed on NASDAQ.

What sector does Olema Pharmaceuticals operate in?

Olema Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze OLMA in a portfolio?

PortView shows OLMA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.